ImageneBio, Inc. (IMA)
4.165
+0.06
(+1.59%)
USD |
NASDAQ |
Nov 05, 16:00
ImageneBio Enterprise Value : -84.70M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -84.70M |
| November 04, 2026 | -85.44M |
| November 03, 2026 | -86.34M |
| November 02, 2026 | -85.55M |
| October 30, 2026 | -85.44M |
| October 29, 2026 | -86.00M |
| October 28, 2026 | -84.31M |
| October 27, 2026 | -86.34M |
| October 26, 2026 | -86.00M |
| October 23, 2026 | -84.08M |
| October 22, 2026 | -86.06M |
| October 21, 2026 | -85.61M |
| October 20, 2026 | -85.10M |
| October 19, 2026 | -86.56M |
| October 16, 2026 | -86.11M |
| October 15, 2026 | -86.23M |
| October 14, 2026 | -84.87M |
| October 13, 2026 | -83.86M |
| October 12, 2026 | -83.74M |
| October 09, 2026 | -83.86M |
| October 08, 2026 | -83.63M |
| October 07, 2026 | -79.68M |
| October 06, 2026 | -79.80M |
| October 05, 2026 | -78.67M |
| October 02, 2026 | -79.80M |
| Date | Value |
|---|---|
| October 01, 2026 | -80.02M |
| September 30, 2026 | -80.02M |
| September 29, 2026 | -80.02M |
| September 28, 2026 | -79.35M |
| September 25, 2026 | -78.44M |
| September 24, 2026 | -79.12M |
| September 23, 2026 | -77.09M |
| September 22, 2026 | -76.98M |
| September 21, 2026 | -77.43M |
| September 18, 2026 | -76.53M |
| September 17, 2026 | -75.06M |
| September 16, 2026 | -76.08M |
| September 15, 2026 | -76.19M |
| September 14, 2026 | -75.29M |
| September 11, 2026 | -74.38M |
| September 10, 2026 | -75.23M |
| September 09, 2026 | -75.17M |
| September 08, 2026 | -74.72M |
| September 04, 2026 | -76.98M |
| September 03, 2026 | -76.58M |
| September 02, 2026 | -75.74M |
| September 01, 2026 | -75.06M |
| August 31, 2026 | -74.16M |
| August 28, 2026 | -71.45M |
| August 27, 2026 | -71.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
| Vericel Corp. | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.18M |
| Total Expenses (Quarterly) | 10.18M |
| EPS Diluted (Quarterly) | -0.6298 |
| Earnings Yield | -124.8% |
| Normalized Earnings Yield | -124.85 |